Introduction {#s1}
============

Polycystic ovary syndrome (PCOS) is a condition of primary ovulatory dysfunction associated with metabolic disturbances ([@DEU187C81]; [@DEU187C77]; [@DEU187C80]; [@DEU187C21]). The consensus definition of PCOS by the European Society for Human Reproduction and Embryology, and the American Society for Reproductive Medicine (ESHRE/ASRM) ([@DEU187C21] is used widely in practice and requires the presence of two out of three features: oligo/amenorrhoea, clinical or biochemical features of hyperandrogenism and/or ultrasound feature of polycystic ovaries. A state of insulin resistance, compensatory hyperinsulinaemia and perturbed glucose metabolism of somatic cells may occur in women with PCOS ([@DEU187C7]; [@DEU187C67]). Insulin-mediated uptake of glucose by peripheral tissues is reduced by 35--45% in women with PCOS when compared with age and weight matched controls ([@DEU187C18].

Recently, marked differences were observed in the way energy substrates were metabolized by sheep follicular GCs compared with other species ([@DEU187C11]). Glucose, metabolized under anoxic conditions to lactate, was shown to be the preferred energy substrate required to support the gonadotrophin-induced differentiation of sheep GCs *in vitro*; fructose and pyruvate, but not galactose, were consumed as alternative sources of energy. In normal human ovaries, it is established that the GCs metabolize glucose by glycolysis and this results in the production of lactate and pyruvate ([@DEU187C3]; [@DEU187C28]; [@DEU187C5]). While the pyruvate so derived is utilized by the oocytes as their energy source, lactate either diffuses into the blood or is converted back to pyruvate ([@DEU187C40]; [@DEU187C6]). The extent of aberrant metabolism present in the GCs from women with PCOS has not been fully investigated ([@DEU187C82]; [@DEU187C59]). Indeed, Purcell *et al.* has demonstrated blunted insulin-stimulated glucose uptake *in vitro* by cumulus cells from women with PCOS ([@DEU187C58]). Previous researchers have also shown that there is an impaired insulin-stimulated lactate production but intact insulin-responsive steroid production by follicular GCs from women with PCOS ([@DEU187C42]; [@DEU187C22]; [@DEU187C59]). Previous studies which have cultured GC over 48 h *in vitro* have demonstrated that insulin-induced glucose uptake by GCs in response to increasing doses of insulin is much lower in GCs from anovulatory patients with PCOS than from women with either normal ovaries or ovulatory polycystic ovaries ([@DEU187C59]). However, caution needs to be exercised as many of these results were obtained by placing the cells in highly unphysiological conditions in serum-containing medium with high glucose and insulin concentrations.

Although insulin has long been recognized as the hormone of glucose utilization ([@DEU187C41]), its role in follicle glucose metabolism and maturation is poorly understood in women with normal ovarian function as well as in women with PCOS. Furthermore, both non-insulin and insulin-dependent glucose transporters (GLUTs), renamed as SLC2A1 and SLC2A4, respectively, have been identified in sheep ovaries ([@DEU187C11]). Moreover, the expression of SLC2A1 and 4 *in vitro* by sheep GCs was modulated by the dose of glucose in the medium. So there are internal mechanisms other than insulin-mediation likely to be involved in glucose transport by GCs. In insulin-responsive tissues, however, insulin plays a key role in signalling for mobilization of GLUT to the cell membrane, facilitating glucose entry into the cell ([@DEU187C77]). The rate-limiting factor in insulin-mediated glucose uptake is the transfer of GLUTs to the plasma membrane ([@DEU187C26]; [@DEU187C71]; [@DEU187C65]). Tyrosine phosphorylation of the insulin receptor (IR) activates the whole insulin cascade and results in glucose uptake by the cells ([@DEU187C19]. Alternatively, serine phosphorylation of the IR may inhibit the insulin cascade ([@DEU187C7]). Whilst there is inconsistency as to which component of the insulin-mediated glycolytic pathway is affected in GCs in women with PCOS, excessive serine phosphorylation has been attributed to the post-binding defect and insulin resistance observed in these women ([@DEU187C57]; [@DEU187C67]; [@DEU187C56]; [@DEU187C66]).

Since insulin resistance and hyperinsulinaemia are central to the pathogenesis of PCOS, it is natural to expect insulin sensitisers to be of benefit in the management of the condition ([@DEU187C53]). Metformin, an insulin sensitiser, is the first-line oral antihyperglycemic drug used in the management of type 2 diabetes mellitus. In insulin-treated type 2 diabetic patients, addition of metformin improves insulin sensitivity and glycemic control while allowing a reduction in the daily insulin dose ([@DEU187C14]). Metformin alone decreases fasting plasma glucose concentration to 4--4.5 mM and HbA1c by 1.5--2.0% in patients with type 2 diabetes mellitus. In addition, metformin has been reported to decrease lipid oxidation and plasma free fatty acid levels thereby improving the cardiovascular risk profile in type 2 diabetic patients. In the U.K. Prospective Diabetes Study, treatment with metformin showed a significant reduction in diabetes-related death, heart attacks and stroke ([@DEU187C83]).

The metabolic actions of metformin on cells include increases in insulin sensitivity of responsive tissues, IR number and affinity in skeletal muscle and adipose cells, conversion of glucose to lactate by erythrocytes, tyrosine kinase activity and glucose uptake ([@DEU187C14]; [@DEU187C48]). Conversely, metformin results in a decrease in glucose absorption by gut, plasma glucagon levels, gluconeogenesis and glycogenolysis in the liver ([@DEU187C63]; [@DEU187C62]; [@DEU187C14]; [@DEU187C78]; [@DEU187C48]).

Chemically, metformin belongs to the biguanide group of compounds and is made of *N*,*N*-dimethylimidodicarbonimidic diamide hydrochloride as indicated below.

Metformin has an absolute oral bioavailability of 40--60% within 6 h of ingestion and a half-life of 4.0--8.7 h ([@DEU187C60]). The total daily therapeutic dose of metformin may be 0.5--3 g usually split into 2 or 3 doses ([@DEU187C64]. It is not bound to any protein and no metabolites have been identified that circulate in the bloodstream ([@DEU187C64]. Side effects of metformin are primarily confined to the gastrointestinal tract such as abdominal discomfort and diarrhoea ([@DEU187C69]; [@DEU187C72],[@DEU187C73]). Lactic acidosis is rare, with an incidence of three cases per 100 000 patient-years of therapy, mainly in those with impaired renal function ([@DEU187C79]).

A key perturbation in women with PCOS is excessive ovarian androgen production and consequently, excessive estrogen production by GCs. Although the improvement in androgen concentrations in the circulating and follicular environment of women with PCOS treated with metformin may bring indirect beneficial effects to the developing oocytes ([@DEU187C47]; [@DEU187C51]), any direct effects of metformin on GC glucose metabolism have yet to be identified. Recently, porcine GCs cultured *in vitro* for 24 h in the presence of metformin and insulin demonstrated enhanced mRNA expressions of insulin receptor substrate-1 (IRS-1) and insulin-like growth factor-1 receptor (IGF-1R), suggesting that metformin could change the metabolic capacity of ovarian GCs ([@DEU187C39]). In the ovary, earlier reports have also characterized various subunits of AMP-activated protein kinase (AMPK) in GCs, theca cells, oocytes and corpora lutea of cows ([@DEU187C24]). Metformin has been shown to activate the AMPK cascade, which in turn takes part in glucose transport into the muscle cell ([@DEU187C24]). Indeed, exposure to metformin has been shown to lead to increased tyrosine kinase activity and 2-deoxy glucose transport in a dose-dependent manner in rat smooth vascular smooth muscle cells suggesting enhanced sensitivity to insulin and IGF-1 ([@DEU187C17]).

The objective of this research was therefore to investigate the capacity for glucose uptake and utilization by human GCs in normal women and women with PCOS with or without prior treatment *in vivo* with metformin with a view to understanding the consequences of the PCOS pathology on the metabolism of the energy resources available to the oocyte during its development within the follicle. For this, glucose uptake and pyruvate and lactate production by GCs were quantified over an acute time frame and after long-term culture. Acute measures of GC metabolism and progesterone production 6 h after oocyte retrieval (OR) reflect the functional capacity of follicular phenotype GCs at the time of oocyte harvest. In contrast, metabolic and steroid measurements made after long-term culture reflect the inherent capacity of GC to adapt and respond to defined glucose and insulin environments *in vitro*. Cultures were established from GCs harvested from individual patients to facilitate direct comparison of GC metabolism *in vitro* with plasma follicular fluid metabolites in the same patient.

Materials and Methods {#s2}
=====================

Ethical approval {#s2a}
----------------

The York Research Ethics Committee approved the research protocol. Reference number: 06/Q1108/76. Written informed consent was obtained from all participants.

Patients {#s2b}
--------

The study population contained three aetiological subgroups, namely, women with normal ovaries (Control *n* = 12), women with PCOS not treated with metformin during their IVF/ICSI treatment (PCOS *n* = 8) and women with PCOS treated with metformin during their IVF/ICSI treatment (Metformin *n* = 8). Within each aetiological group, the number of subjects completing different components of the GC research varied. Relevant *n* values are given in respective tables and graphs.

Women attending the assisted conception units at Leeds General Infirmary and St James\'s University Hospital, aged 20--39 years with normal serum FSH concentrations (1--8 IU/l) were recruited to donate their GCs for research. Those women who met the Rotterdam criteria ([@DEU187C21] were classified as having PCOS. Full blood count and liver function tests were conducted in women with PCOS before receiving metformin. Those women with a BMI \>30 kg/m^2^ also underwent a glucose tolerance test and fasting lipid profile ([@DEU187C80]). Women with impaired glucose tolerance and diabetes were excluded from the study.

Study participants received a long agonist protocol for their IVF treatment. Nafarelin acetate (200 mcg three times per day, Pharmacia, Milton Keynes, UK), buserelin (0.5 mg per day, Pharmacia, Milton Keynes, UK) or leuproline acetate (Prostap 3.75 mg single dose, Wyeth Laboratories, Hants, UK) was used for pituitary down-regulation. Controlled ovarian hyperstimulation was achieved following delivery of either urinary or recombinant FSH. None of the participants received a mixed stimulation protocol. For those women receiving metformin, treatment was commenced at a dose of 850 mg twice daily from the day of start of down-regulation with GnRH agonist and continued until the day of OR. The follicular response was considered to be satisfactory for an adequate yield of GCs when there were at least 10 follicles of at least 13 mm diameter present on the transvaginal ultrasound scan on the last day of stimulation, of which at least 3 follicles were ≥17 mm in diameter. Ovulation was triggered in all subjects from the three groups by injection of 5000--10 000 IU of the same hCG preparation (Pregnyl, Organon, Welwyn Garden City, Herts, UK) and transvaginal oocyte retrieval was performed 34--36 h later. On the day of OR, peripheral blood samples were obtained for the estimation of fasting serum glucose and insulin concentrations. At the time of transvaginal OR, a clean sample of follicular fluid was collected from one or both ovaries. Cellular contaminants were removed by centrifugation at 900 g for 10 min prior to storing the supernatant at −80°C for later analysis. Following recovery of oocytes, the residual GCs in the follicular aspirates from individual patients were processed for culture.

Granulosa cell harvest and culture {#s2c}
----------------------------------

Reagents were purchased from Sigma-Aldrich Company Ltd, (Dorset, UK) unless otherwise stated. Modified McCoy\'s 5A medium (SAFC Biosciences, Hampshire, UK) without glucose and glutamine was used as the base medium for GC preparation and culture. Medium was supplemented with [l]{.smallcaps}-glutamine (210 mg/l), 0.1% human serum albumin (C.A.F-D.C.F. cvba-scrl, Brussels, Belgium), Penicillin-G/ Streptomycin (100 IU/ml/100 µg/ml), HEPES, human transferrin (5 µg/ml), sodium selenite selenium (5 ng/ml), Long R3 IGF-I (100 ng/ml), recombinant FSH (0.5 mU/ml) (Gonal-F: Merck-Serono, UK) and recombinant hCG (0.05 mU/ml) (Ovitrelle: Merck-Serono, UK). All media were pre-equilibrated to 37°C and 5% CO~2~ in air in a humidified incubator.

Follicular aspirates from individual patients were centrifuged at 900 g at room temperature. Blood contaminants were removed from GCs by Histopaque 1700 gradient centrifugation at 900 g at room temperature. The GC pellet was resuspended in 20 ml volume of medium and washed by a further 10 min centrifugation. The GC pellet was resuspended in 1 ml of GC preparation medium containing 0.02% (w/v) EDTA and gentle repeated pipetting was carried out to break up cellular clumps. After further washing, the cell stock was finally resuspended in 1 ml of GC culture medium.

Viable GC number was counted by trypan blue dye exclusion ([@DEU187C55]) and cells were seeded at a concentration of 1 × 10^5^ viable cells per well into 250 µl of McCoy\'s 5A culture medium which had been further supplemented with varying doses of insulin (0, 0.01, 0.1, 1, 10 and 100 ng/ml) and glucose (0, 3 and 6 mM). Cells were cultured in 96-well flat bottom Nunc culture plates (NUNC, Scientific Laboratory Supplies, Wilford, Nottingham, UK) at 37°C and 5% CO~2~ in a humidified incubator. Each glucose/insulin treatment was tested in triplicate for each patient. In the physiological, serum-free culture conditions used in the present experiments the GCs did not attach to the plastic matrix of the culture dish nor did they form the flattened, fibroblastic monolayers which are typical of serum- and/or extracellular matrix-based culture systems. In the culture conditions reported here, the GCs formed discrete, free-floating, 3-dimensional clumps of rounded cells which were resonant of the follicular phenotype of GCs seen *in vivo*. These non-adherent GC cultures did not attain confluence *in vitro*.

For assessment of acute GC metabolism reflective of the follicular environment, spent culture media was collected after 6 h of incubation by the removal and replacement of 140 µl of medium. Thereafter, culture media was refreshed at 48, 96 and 144 h by removal and replacement of 150, 200 and 150 µl of media, respectively. The 6 h incubation time used to quantify acute, follicular GC metabolism at the time of OR was based on the outcome of a series of 10 replicate, individual patient validation cultures and reflected the minimal time required to accurately quantify the turnover of all three metabolites by 1 × 10^5^ viable GCs *in vitro*. In the long-term culture studies, the intermediate media change time points and total duration of culture (144 h) used have been extensively validated for the same culture system using ovine, porcine and bovine GCs and have been shown to provide accurate time points for the measurement of steroidogenesis and metabolism by GCs in response to defined culture conditions *in vitro* ([@DEU187C9]; [@DEU187C55]). Spent media were stored at --80°C for assays of glucose, pyruvate and lactate turnover and progesterone production. After 144 h of culture, GC number and viability was evaluated by measuring the uptake of the vital dye, Neutral Red ([@DEU187C9]; [@DEU187C55]).

The glycolytic index ratio is expected to be 2:1 when glucose is fully metabolized by oxygen-independent glycolysis to its final end product lactate via pyruvate ([@DEU187C29]). A lower ratio is indicative of a drop in the formation of lactate whereas a higher ratio is indicative of lactate production from extra sources such as intracellular glycogen in addition to oxygen-independent glycolysis of the exogenous glucose supplied to the cells.

Serum and follicular fluid glucose and insulin assays {#s2d}
-----------------------------------------------------

Serum and follicular fluid glucose and insulin assays were carried out at the routine Clinical Biochemistry Laboratory at Leeds General Infirmary. Serum and follicular fluid glucose was measured by the glucose oxidase method using ADVIA systems (Siemens Healthcare Diagnostics, Inc., Camberley, UK), designed for estimation in human serum, plasma, urine and other body fluids. The analytical range was 0--41.6 mmol/l. All assays were performed according to manufacturer\'s instructions. Glucose was measured after enzymatic oxidation in the presence of glucose oxidase. Routine Quality Controls (QCs), both internal and external, were performed as per the laboratory quality standards. The between-batch coefficient of variation (CV) was \<5%.

Serum insulin concentrations were measured by immunochemiluminometric assay using ADVIA Centaur Insulin (Siemens Healthcare Diagnostics), designed for measurement of insulin in serum and plasma. The results were reported in mU/l and converted to ng/ml for presentation. Insulin resistance was calculated using the quantitative insulin sensitivity check index method (QUICKI = 1/((log (fasting insulin µU/mL) + log (fasting glucose mg/dl))) ([@DEU187C45]).

To validate the measurement of follicular fluid insulin, insulin standards were prepared using recombinant human insulin, 3 IU/vial (National Institute for Biological Standards and Control (NIBSC), 1st International reference preparation 66/304). Insulin recovery from diluted follicular fluid was checked in triplicates and ranged from 81 to 98%. Recovery of exogenous insulin was validated by addition of 10 μl of insulin stock with a known concentration of insulin to 1 mL of follicular fluid followed by serial dilution and the recoveries ranged from 91 to 118%. After validation, the assays were run according to the ADVIA Centaur Reference Manual. All samples from follicular fluid were analysed in a single batch. The within-assay CVs were 3, 5 and 4% at low (18.6--27.9 pmol/l), medium (69.6--86.6 pmol/l) and high (203.1--252.1 pmol/l) concentrations of insulin-QCs, respectively.

Assays of GC metabolism {#s2e}
-----------------------

Metabolites were measured using enzyme-linked spectrophotometric/fluorometric assays on a 96-well plate reader (Biolinx MRX plate reader, Dynatech Laboratories, San Diego, CA, USA). The concentrations of metabolites measured in the spent media at each time point were used to calculate the rate of metabolism of viable cells per well after 144 h of culture, after accounting for any carry-over of metabolites during media changes at the intermediate time points. The colour changes for each metabolite were proportional to the amount of glucose, pyruvate and lactate in the spent media. Lactate was measured by monitoring the increase in fluorescence due to the conversion of NAD to NADH; pyruvate by a decrease in fluorescence due to the oxidation of NADH; and glucose by an increase in fluorescence due to the formation of NADPH from NADP ([@DEU187C34]). The assay sensitivity was 0--10 mM for glucose/lactate and 0--2 mM for pyruvate. The assay reaction time was 10, 30 and 5 min for glucose, lactate and pyruvate, respectively. Each metabolism assay included cell-free culture controls and assay control QCs spiked with known concentrations of metabolites (low and high concentration within the sensitivity range). The intra- and inter-assay CVs were \<10% for all metabolites except for the acute culture pyruvate assays where the CV was \<20%.

Progesterone assays {#s2f}
-------------------

Progesterone measurements were carried out using an enzyme-linked immunosorbent assay in the laboratory at the Division of Obstetrics and Gynaecology, School of Clinical Sciences, Queens Medical Centre, Nottingham University. Assays were performed utilizing a progesterone antibody (SAPU R7044X) previously validated for radioimmunoassay ([@DEU187C10]) in combination with a Progesterone-3-Horse Radish Peroxidase conjugate obtained from Abiox plc (Newberg OR, USA). The limit of detection was \<39 pg/ml, and the intra- and inter-assay CVs were 5 and 11%, respectively. The progesterone production rate per cell per hour was calculated from the concentrations of progesterone measured after correction for carry over effects during media changes.

Statistical analysis {#s2g}
--------------------

All metabolite and hormone production/consumption data were expressed per hour per 1 × 10^5^ viable GCs. Categorical data in the patient demographics were converted to percentages before analysis. The Chi-squared test was used to investigate differences between categorical variables such as fertilization rate and pregnancy rate. Metabolite and steroid data from all three groups were normalized by log-transformation (log~10~ (*x* + 1)). Viable cell number data after 144 h of culture were log transformed prior to analysis. A multivariate analysis of variance (ANOVA) was used to test the effects of culture treatment on cell metabolism; Bonferroni *post hoc* test was used to test the difference between means. Univariate-repeated measure ANOVA was carried out to determine the effects of insulin and glucose concentrations on cultured GC between 6 h and 144 h of culture. In all cases, *P* \< 0.05 was considered to be statistically significant. Both, STATA 10.2 and SYSTAT 15, statistical packages were used appropriately for data analysis. The glycolytic index was calculated as the ratio of number of moles of lactate produced from one mole of glucose consumed.

Results {#s3}
=======

Patient demographics {#s3a}
--------------------

The subjects from all three groups were matched for their age, duration of infertility, BMI and baseline serum FSH (Table [I](#DEU187TB1){ref-type="table"}). All groups of patients received a comparable total dose of FSH over a similar duration for controlled ovarian hyperstimulation. The number of mature oocytes per patient was lower in the PCOS group than the Controls and the difference just reached significance (*P* = 0.046). The fertilization rate per metaphase II oocyte, positive pregnancy rate and clinical pregnancy rates were similar in all three groups. Table IDemographics of the participants of the granulosa cell metabolism studies.Clinical dataControl (*n* = 12)PCOS (*n* = 8)Metformin (*n* = 8)SignificanceAge (years)34.4 ± 1.431.5 ± 1.234.4 ± 1.3nsDuration of infertility (years)3.2 ± 0.74.1 ± 0.83.4 ± 0.7nsBMI (kg/m^2^)25.5 ± 1.626.0 ± 1.929.8 ± 1.5nsSerum FSH (IU/l)6.8 ± 0.65.5 ± 0.55.7 ± 0.5nsTotal days of stimulation10.2 ± 0.212.4 ± 0.910.4 ± 0.5nsTotal dose of exogenous FSH IU2405 ± 2642692 ± 3821885 ± 303nsTotal number of follicles developed23.3 ± 2.031.1 ± 3.023.8 ± 4.0nsNumber of MII oocytes/patient16.3 ± 2.012.4 ± 2.811.1 ± 1.0PCOS versus Control, *P* = 0.046 Others -- nsFertilization rate/MII oocyte67 ± 0.2%67 ± 0.2%60 ± 0.2%nsPositive pregnancy rate per cycle started50%75%63%nsClinical pregnancy rate per cycle started50%57%44%ns[^1][^2]

There were no differences in the mean fasting serum concentrations of glucose, insulin or insulin resistance index between the three treatment groups (Table [II](#DEU187TB2){ref-type="table"}). Similarly, there were no significant differences in the mean follicular fluid glucose and insulin concentrations between the three groups and there was no statistically significant relationship between serum and follicular fluid glucose and insulin. Table IIComparison of biochemical parameters between three groups.Sample typeControlPCOSMetforminSignificanceFasting glucose (mM)Serum4.5 ± 0.1 (*n* = 9)4.2 ± 0.1 (*n* = 8)4.5 ± 0.3 (*n* = 8)nsFasting insulin (ng/ml)Serum0.2 ± 0.1 (*n* = 9)0.4 ± 0.1 (*n* = 8)0.3 ± 0.1 (*n* = 8)nsQUICKI insulin resistance indexSerum0.41 ± 0.1 (*n* = 9)0.4 ± 0.3 (*n* = 8)0.4 ± 0.2 (*n* = 8)nsGlucose (mM)Follicular fluid2.7 ± 0.9 (*n* = 4)3.2 ± 0.2 (*n* = 5)3.3 ± 0.5 (*n* = 6)nsInsulin (ng/ml)Follicular fluid50 ± 21 (*n* = 4)14 ± 10 (*n* = 5)41 ± 9 (*n* = 6)ns[^3]

Acute GC metabolism {#s3b}
-------------------

### Effect of aetiology on acute granulosa cell metabolism {#s3b1}

There was no demonstrable effect of insulin concentration in the culture medium on acute glucose consumption, or pyruvate and lactate production, justifying pooling of all results for various insulin doses. There was, however, a significant effect of patient aetiology on acute (6 h) GC glucose consumption, and pyruvate and lactate production (*P* \< 0.001, Fig. [1](#DEU187F1){ref-type="fig"}A). Overall, glucose consumption and pyruvate production by GCs from women with PCOS were significantly (*P* \< 0.05) lower than that of Controls. Conversely, GCs from women with PCOS not exposed to metformin *in vivo* produced significantly (*P* \< 0.05) more lactate than Control GCs. Metformin-pretreatment *in vivo* appeared to 'normalize' the glycolytic pathway of GCs by increasing their acute pyruvate production and decreasing their mean lactate production. However, lactate production by metformin-pretreated GCs still remained significantly (*P* \< 0.05) higher than that of Control GCs (Fig. [1](#DEU187F1){ref-type="fig"}A). Figure 1The effect of aetiology (**A**) and aetiology-glucose interaction (**B**) on acute glucose consumption, pyruvate and lactate production by granulosa cells (GCs) at 6 h of culture. Values plotted are mean ± SEM of the log-transformed data for the number of individual patient cultures shown. Data have been standardized according to viable cell number plated. Different letters on graphs in (A) indicate significant differences between the three aetiological groups tested for each metabolite (*P* \< 0.05). Different letters on graphs in (B) indicate significant differences (*P* \< 0.05) between the three aetiological groups within each glucose dose.

### Effect of glucose concentration on acute GC metabolism {#s3b2}

There was a significant (*P* \< 0.05) effect of the glucose concentration in the culture medium on acute glucose consumption, pyruvate and lactate production by human GCs *in vitro*. As expected, glucose consumption was negligible in cells cultured in glucose-free media but there was no difference in the glucose uptake between cells incubated in 3 and 6 mM glucose. Cells lacking glucose produced little pyruvate *in vitro* but when glucose was available in the medium, there was a significant (*P* \< 0.001) dose-responsive decrease in overall pyruvate production; 3.5 ± 0.1 nmol/l/h/1 × 10^5^ viable GCs at 3 mM glucose compared with 2.5 ± 0.1 nmol/l/h/1 × 10^5^ viable GCs at 6 mM glucose in the medium. Lactate production was limited (2.8 ± 0.2 nmol/l/h/1 × 10^5^ viable GCs) in the absence of glucose, possibly from conversion of the intracellular glycogen reserve. There was an overall significant (*P* \< 0.001) rise in lactate production, which corresponded to the increase in glucose in the medium (31.1 ± 1.1 nmol/l/h/1 × 10^5^ viable GCs for 3 mM glucose and 39.5 ± 1.5 nmol/l/h/1 × 10^5^ viable GCs for 6 mM glucose).

### Interaction between aetiology and glucose concentration on acute GC metabolism {#s3b3}

There was a significant (*P* \< 0.001) interaction between patient aetiology and the glucose concentration in the GC incubation medium that influenced acute GC metabolism *in vitro* (Fig. [1](#DEU187F1){ref-type="fig"}B). At the 3 mM physiological glucose concentration, exposure of PCOS GCs to metformin *in vivo* significantly (*P* \< 0.05) increased acute glucose uptake and pyruvate production, bringing the turnover of these two metabolites closer to the Control group. Glucose consumption by PCOS GCs was significantly (*P* \< 0.05) lower than Control and Metformin GCs when incubated with 3 mM glucose (Fig. [1](#DEU187F1){ref-type="fig"}B).

There was no significant difference in glucose consumption between the three groups when the media glucose concentration was 6 mM. While pyruvate production by Control GCs was significantly (*P* \< 0.001) higher than that by the PCOS GCs at 6 mM glucose, metformin-exposed GCs were mid-way between the PCOS and Control groups at 6 mM glucose dose (Fig. [1](#DEU187F1){ref-type="fig"}B).

Granulosa cells from women with PCOS produced significantly (*P* \< 0.05) more lactate than Control GCs at both 3 and 6 mM glucose. Furthermore, GC lactate production on incubation with 3 mM glucose *in vitro* was significantly (*P* \< 0.001) reduced relative to PCOS cells following metformin-pretreatment *in vivo* matching the levels recorded for Control cells (Fig. [1](#DEU187F1){ref-type="fig"}B).

Effect of metformin exposure *in vivo* on viable GC number *in vitro* {#s3c}
---------------------------------------------------------------------

The GC viability was quantified in all those subjects whose GCs successfully completed 144 h of culture. The results showed a significant change in the number of viable cells between the start and the end of extended culture (Fig. [2](#DEU187F2){ref-type="fig"}). There was no effect of glucose or insulin dose including zero doses on viable GC number at the end of the extended cultures; hence the results were pooled for all glucose and insulin doses. There was, however, a strong effect of aetiology on GC viability such that, exposure to metformin *in vivo* resulted in a significantly higher number of viable GCs (*P* \< 0.05, Fig. [2](#DEU187F2){ref-type="fig"}) after 144 h of culture compared with GCs from the PCOS or Control groups. Figure 2The effect of aetiology on GC viability after 144 h of culture. The values plotted are mean ± SEM of the log-transformed data for the number of individual patient cultures shown. Different letters on the graph indicate significant differences (*P* \< 0.05) between the aetiologies. The dotted line represents the plating density of viable cells per well at the start of the culture.

Long-term GC metabolism {#s3d}
-----------------------

Glucose, pyruvate and lactate metabolism remained detectable in GCs after 144 h of culture. There was no demonstrable effect of insulin at any of the doses tested (data not shown), justifying pooling of data. Glucose consumption and utilization by GCs was detected in the absence of insulin supplementation. There was also no significant interaction between aetiology and insulin content in the medium following long-term culture of GCs.

### Effect of aetiology on long-term GC metabolism {#s3d1}

Overall glucose uptake by Control GCs was significantly (*P* \< 0.05) higher than that of PCOS and PCOS GCs from women pretreated with metformin *in vivo* prior to GC recovery. Control GCs metabolized significantly (*P* \< 0.0001) more glucose than PCOS and Metformin GCs (Fig. [3](#DEU187F3){ref-type="fig"}A). There was a clear effect of aetiology on pyruvate production such that the Control GCs produced significantly (*P* \< 0.0001) more pyruvate than the other two groups at all doses of glucose and insulin tested. Pyruvate production by PCOS GCs was less than that of Control GCs, but higher than Metformin GCs (*P* \< 0.01 and *P* \< 0.05, respectively, Fig. [3](#DEU187F3){ref-type="fig"}A). Mean lactate production by GCs for the three aetiologies is also shown in Fig. [3](#DEU187F3){ref-type="fig"}A. Although the PCOS GCs produced more lactate than Control GCs, this difference was not significant for either 3 mM or 6 mM glucose. The metformin-pretreated GCs produced significantly (*P* \< 0.0001) less lactate than either Control GCs or their PCOS counterparts for all glucose doses tested (Fig. [3](#DEU187F3){ref-type="fig"}A). Figure 3The effect of aetiology (**A**) and glucose dose in the culture medium (**B**) on glucose consumption, pyruvate and lactate production by GCs after 144 h of culture. The values are mean ± SEM of the log-transformed data for the number of individual patient cultures shown. Data have been standardized according to viable cell number measured after 144 h of culture. Different letters on the graphs indicate significant differences (*P* \< 0.05) between the three aetiological groups and the glucose doses tested for each metabolite.

### Effect of glucose concentration on long-term GC metabolism {#s3d2}

The glucose concentration in the medium significantly (*P* \< 0.0001) influenced the overall glucose uptake by the GCs but the observed difference was mainly between GCs cultured in the absence versus the presence of glucose in the medium rather than between 3 and 6 mM glucose doses (Fig. [3](#DEU187F3){ref-type="fig"}B). Although there was a dose-dependent drop in pyruvate production by all three aetiologies when the glucose supply in the medium was increased from 3 to 6 mM; this effect was not significant (*P* \> 0.05). Similar to acute GC metabolism, there was a trend (*P* = 0.053) for an increase in overall lactate production in response to the presence of higher glucose in the medium (Fig. [3](#DEU187F3){ref-type="fig"}B).

### Interaction between aetiology and glucose dose on long-term GC metabolism {#s3d3}

The only metabolite turnover which demonstrated a strong tendency (*P* = 0.05) for an interaction between patient aetiology and glucose dose was lactate production after 144 h of culture. There was a significant (*P* \< 0.05) increase in the overall lactate production rate in response to the glucose concentration in the medium in the Control and PCOS groups while the increment was not significant in the Metformin group.

### Metabolite turnover rate over 144 h {#s3d4}

In order to capture the impact of the defined culture conditions on GC metabolism, the mean percentage differences in the rate of GC metabolism per viable cells between 6 and 144 h of cultures were analysed for all three aetiological groups. The results demonstrate significant differences between the aetiologies in the way the GCs utilized glucose and produced lactate and pyruvate over 144 h (Fig. [4](#DEU187F4){ref-type="fig"}). Figure 4The effects of aetiology on percentage increase (positive values) or decrease (negative values) in glucose consumption and pyruvate and lactate production rate per 1 × 10^5^ viable GCs per well over 144 h of culture. The values plotted are mean ± SEM of the data for the number of individual patient cultures shown. Asterisk indicates significant difference (*P* \< 0.05) between the aetiologies for the metabolite shown.

### Progesterone production by GCs {#s3d5}

Progesterone production data were available for 24 patients. There was no effect of glucose or insulin doses including zero doses on acute or long-term progesterone production; therefore the data were pooled for further analysis. Measurable progesterone production was detectable for GCs after 6 h of culture and a significant (*P* \< 0.0001) difference was observed between the three aetiologies such that Control GCs produced significantly (*P* \< 0.0001) more progesterone than either PCOS GCs or metformin-pretreated GCs (Fig. [5](#DEU187F5){ref-type="fig"}). Similarly, after 144 h of culture, there was a significant difference (*P* \< 0.0001) in the long-term progesterone production by GCs from the three aetiological groups (Fig. [5](#DEU187F5){ref-type="fig"}). After long-term culture, the highest progesterone synthesis was reported for Control GCs, followed by PCOS GCs and finally by the metformin-pretreated group. Metformin exposure *in vivo* had no significant effect on acute progesterone production compared with untreated PCOS GCs. While the Control and PCOS GCs not exposed to metformin *in vivo* maintained their progesterone production over time, the Metformin GCs significantly (*P* \< 0.0001) dropped their progesterone production over 144 h of culture *in vitro*. Figure 5The effects of aetiology and duration of culture on overall progesterone production by GCs. The values plotted are mean ± SEM of the log-transformed data for the number of individual patient cultures shown. Data have been standardized according to viable cell number. a and b indicate significant difference (*P* \< 0.05) between the aetiological groups at 6 h of culture (6 h) and x, y and z indicate significant difference (*P* \< 0.05) between the aetiological groups at 144 h of culture (144 h). Asterisk indicates significant difference (*P* \< 0.05) within aetiology at the two time points shown.

### The glycolytic index of GCs {#s3d6}

Both aetiology and glucose content of the culture medium had a significant (*P* \< 0.001) effect on the acute glycolytic index of GCs. The PCOS GCs demonstrated the highest glycolytic index (2.6 ± 0.2, *n* = 8), relative to metformin-pretreated GCs (2.1 ± 0.1, *n* = 8) and Control GCs (1.8 ± 0.1, *n* = 9) (Fig. [6](#DEU187F6){ref-type="fig"}). The differences in the glycolytic index between Control and PCOS GCs and metformin-pretreated PCOS GCs were significant (*P* \< 0.001; *P* \< 0.05, respectively). Metformin-pretreatment shifted the glycolytic index of GCs towards that of Control GCs so that there was no statistical difference between the two groups. The acute glycolytic index increased significantly (*P* \< 0.01) with increasing glucose concentration in the medium irrespective of patient aetiology and insulin dose (1.8 ± 0.1, *n* = 25 and 2.3 ± 0.1, *n* = 25 at 3 mM and 6 mM glucose supply, respectively). A rise in the glycolytic index in response to the glucose content in the medium is consistent with increased lactate and decreased pyruvate production by the GCs in response to the glucose supply. Figure 6The effects of aetiology and duration of culture on the glycolytic index of GCs. The values plotted are mean ± SEM of the data for the number of individual patient cultures shown. a and b indicate significant difference (*P* \< 0.05) between the aetiological groups at 6 h of culture (6 h) and x and y indicate significant difference (*P* \< 0.05) between the aetiological groups at 144 h of culture (144 h).

In the long-term cultures, once again there was a strong and significant (*P* \< 0.0001) effect of patient aetiology on the glycolytic index of GCs. The glycolytic index was lowest in Control GCs (2.0 ± 0.1, *n* = 6) and was significantly (*P* \< 0.0001) different to that of PCOS (2.8 ± 0.2, *n* = 7) and Metformin GCs (2.7 ± 0.1, *n* = 8). Unlike after acute (6 h) culture, none of the GCs showed noticeable changes in the glycolytic index in response to glucose content in the medium after extended culture (144 h). Moreover, metformin-pretreatment did not produce any change in the glycolytic index after extended culture. Overall, the metabolism results indicated preferential lactate production by PCOS GCs compared with Control GCs (Fig. [6](#DEU187F6){ref-type="fig"}).

Discussion {#s4}
==========

This research has, for the first time, provided detailed insights into glucose metabolism in defined environments *in vivo* and *in vitro* by GCs from women with PCOS with a view to characterizing the exact metabolic lesion in these cells. The results have shown that all three components of glycolysis namely, glucose uptake and pyruvate and lactate production, are perturbed in women with PCOS. Previous studies have indicated that insulin-induced lactate production *in vitro* by GCs was impaired in women with anovulatory PCOS compared with controls ([@DEU187C42]; [@DEU187C22]; [@DEU187C59]). In contrast, the acute metabolism results from the current study revealed higher lactate production by PCOS GCs than Controls irrespective of the insulin concentration in the culture medium. Similarly, long-term lactate production was also comparable between Control and PCOS GCs without any demonstrable insulin effect. It is to be noted that the previously reported impaired insulin-stimulated lactate production was only recorded after exposure of cells to supra-physiological doses of insulin, which were higher than the top dose (100 ng/ml) used in the present studies ([@DEU187C42]; [@DEU187C22]; [@DEU187C59]). Caution needs to be exercised in making a direct comparison between published studies and the present work. In the current study, GC metabolism was measured after 6 and 144 h of culture whereas in previous studies, the metabolites were measured after 48--72 h of culture only. Moreover, the current data on GC metabolism were generated on GCs harvested from individual patients cultured in a serum-free culture system containing sub- to supra- physiological doses of glucose and insulin, and physiological concentrations of hCG (0.05 mU/ml) and FSH (0.5 mU/ml) ([@DEU187C55]). In contrast, [@DEU187C59] used an LH dose range of 0, 2.5 and 5 ng/ml (equivalent to 0, 0.01 mU/ml and 0.22 mU/ml of LH) and a range of insulin concentrations up to a higher maximum dose of 1000 ng/ml to stimulate the GC metabolism in a serum-based culture system containing 5.5 mM glucose.

The present study also reports that the glycolytic index of Control GCs was \<2, suggesting that each mole of glucose was not fully metabolized to lactate, the end product of oxygen-independent glycolysis, instead metabolized to other molecules like pyruvate ([@DEU187C30]). The index was \>2 for PCOS GCs, which is indicative of complete glycolysis of each mole of glucose to two moles of lactate and additional lactate production possibly from intracellular glycogen. The results lead us to hypothesize that preferential conversion of glucose to the intermediate metabolite pyruvate occurs in Control GCs, while the preferential accumulation of the end product of glycolysis lactate occurs in women with PCOS. These data are relevant to women undergoing assisted conception, as pyruvate is the key energy substrate for the pentose phosphate pathway and so plays a central role in generating the nucleotides which are essential for oocyte nuclear maturation and developmental competence ([@DEU187C70]). Lack of pyruvate production by PCOS GCs may, therefore, compromise the developmental capacity and hence the quality of the oocytes from women with this pathology.

An important finding of the current experiments was the lack of demonstrable effects of insulin in the culture medium on acute or long-term glucose metabolism by the human GCs. This observation suggests that insulin resistance is predominantly an *in vivo* phenomenon, which is not consistently present in cultured granulosa lutein cells collected from women with PCOS undergoing assisted conception. In support of this explanation, insulin resistance has not always been demonstrated *in vitro* in somatic cells from women with PCOS. For example, cultures of skeletal muscle cells failed to show differences in insulin sensitivity between PCOS and control subjects ([@DEU187C13]). Similarly, insulin binding and insulin-responsive basal glucose transport were comparable between control and PCOS adipocytes whereas the insulin sensitivity, as assessed by adenosine-depleted glucose transport activity, was impaired in PCOS adipocytes ([@DEU187C12]). The possible explanation given for failure to demonstrate insulin resistance *in vitro* in these previous studies was that the factors such as hyperinsulinaemia, hyperandrogenism and hyperglycaemia, contributing to insulin resistance *in vivo* were not operating *in vitro*. Moreover, insulin resistance *in vivo* is believed to be due to post-receptor signalling defects in tyrosine phosphorylation rather than a problem in the IR affinity and function ([@DEU187C37]; [@DEU187C77]; [@DEU187C19]). Alternatively, factors such as IGF-1 and gonadotrophins may play a more important role than insulin in regulating glucose uptake and utilization by human GCs at least in the present serum-free cultures *in vitro*. In this context, the inclusion of LR3 IGF-1 in the culture medium might have overridden any effect of insulin on cellular glucose metabolism, albeit, such an overriding effect might have required a much higher dose than the physiological level (100 ng/ml) used in the current experiment. Indeed, most of the published reports on glucose metabolism by PCOS GCs have tested the insulin-responsiveness of the cells in the absence of IGF-1 ([@DEU187C42]; [@DEU187C22]; [@DEU187C59]). When [@DEU187C84] compared the effects of insulin and IGF-1 on human GC glucose metabolism, the results showed that the affinity and effect of IGF-1 was much more potent than that of insulin on GC glucose uptake in women with PCOS. Conversely, some researchers have proposed that the GC response to insulin in women with PCOS is mediated by the IR rather than IGF ([@DEU187C82]). Nevertheless, there is increasing support for the notion that a cross-link between the IR and IGF-1R could lead to an overlap of metabolic activities in cells ([@DEU187C4]. Moreover, it has been proposed that IR/IGF-1R-hybrid receptors may be present in GCs, leading to uptake of glucose via IGF-1 stimulation ([@DEU187C43].

The mean serum and follicular fluid glucose concentrations (4.4 ± 0.1 mM and 3.1 ± 0.3 mM, respectively) were comparable to that reported by earlier studies ([@DEU187C40]; [@DEU187C54]; [@DEU187C59]; [@DEU187C49]). As reported previously in the literature, the follicular fluid (a filtrate of plasma) glucose concentration was much lower than that in serum ([@DEU187C40]) while the opposite was observed for insulin. This observation supports the notion that follicle cells may not contain insulin-sensitive glucose transporters, leading to accumulation of insulin in the follicular fluid ([@DEU187C11]).

Treatment of women with PCOS with metformin during their IVF cycles clearly 'normalized' the acute glucose metabolism in GCs incubated with a physiological concentration of glucose (3 mM). It is likely that the mechanism by which metformin enhances glucose consumption by the GCs from women with PCOS may directly enhance pyruvate production by the same cells. The present findings for GCs are consistent with the metabolic behaviour of metformin-treated hepatocytes in culture that show an increase in insulin-stimulated glucose uptake, IR phosphorylation-activated glucose intake and glycolysis ([@DEU187C25]; [@DEU187C27]). Enhanced activity of hexokinase and pyruvate kinase was proposed to be responsible for such effects of metformin. Similarly, metformin treatment over a period of 10 weeks increased the glucose uptake by skeletal muscle cells in subjects with type 2 diabetes mellitus via the AMPK pathway ([@DEU187C48]). However, pyruvate production observed in the GCs in the present study was not fully corrected to the Control levels following exposure to metformin *in vivo*. Whether increasing the clinical dose of metformin would further improve GC metabolism is a question for further research. Furthermore, the question of whether the observed metformin-induced improvement in acute GC metabolism is translated into clinical effectiveness needs further investigation. Previously, metformin pretreatment *in vivo* has shown no significant effect on *in vitro* maturation potential of immature sibling PCOS oocytes produced during IVF treatment ([@DEU187C31]). In line with the available literature, the current study showed no difference in the fertilization rate per mature oocyte, positive pregnancy rate per cycle or clinical pregnancy rate per cycle between the groups. A recent meta-analysis by [@DEU187C52a] also confirmed that the use of metformin during IVF/ICSI treatment did not improve pregnancy or live birth rates. In contrast, metformin treatment has been shown to double live birth rates, most probably by reducing the cancellation rate, when the drug is administered during gonadotrophin-stimulated ovulation induction ([@DEU187C52]).

The underlying mechanism for the observed increase in viable cell number in PCOS and metformin-pretreated GCs is unclear. The GCs from early antral follicles (0.5--2 mm in diameter) have the potential to proliferate in physiological, serum-free culture when stimulated appropriately, while cells from larger antral follicles (\>5--6 mm in diameter) more commonly tend to differentiate if viable cell number is maintained *in vitro*, as evidence by their increased capacity to aromatize androgens to estrogens ([@DEU187C8]; [@DEU187C9]; [@DEU187C32]). The granulosa lutein cells used in the present experiments were predominantly harvested from larger antral follicles and, further, they were already terminally differentiated on collection following exposure to the hCG trigger *in vivo*. Any direct impact of exogenous LH on terminal follicular development prior to hCG-induced luteinization was not measured and was perhaps a limitation of the study. The inherently reduced apoptosis of PCOS GCs may contribute to the increased viable cell number observed at the end of long-term cultures. In support of this idea, women with PCOS showed higher rates of proliferation and lower rates of apoptosis in GCs collected from unstimulated follicles (4--8 mm diameter) when compared with normal controls ([@DEU187C15]). While activated caspase-3, an enzyme required for cell apoptosis, has been found to be significantly lower, the expression of cell survival proteins, such as islet-activating protein and Bcl gene-2 protein, has been found to be higher in GCs from women with PCOS compared with healthy women. A recent report also suggests that metformin-pretreatment during IVF may directly sensitize human GCs and so result in the increased proliferation of primary GC lines in culture as well as the increased basal cell viability of human granulosa lutein cells *in vitro*, in the absence of any stimulatory effect from insulin or IGF-1 in the media ([@DEU187C68]). Indeed, increased viable cell numbers may also be due to an effect of metformin on the AKT pathway ([@DEU187C33]) or a direct suppression of cell cycle arrest by metformin that is independent of insulin ([@DEU187C35]).

It is striking that the PCOS GCs studied in our experimental series consistently produced less progesterone than Control GCs in both the acute and extended cultures, suggesting that there is an inherently reduced capacity to synthesize progesterone in this aetiology. In support of this idea, [@DEU187C16] has reported reduced progesterone synthesis *in vitro* by luteinized PCOS GCs. Further, FSH and/or IGF-1-induced progesterone secretion in cultures of GCs from 8- to 10-mm-sized unluteinized follicles from women with PCOS was significantly lower than control GCs, supporting inherent perturbation in the steroidogenic capacity of PCOS GCs ([@DEU187C20]). An important manifestation of the observed reduced progesterone biosynthesis by PCOS GCs *in vivo* may be a luteal phase deficiency of progesterone synthesis and associated poor pregnancy outcomes ([@DEU187C46]; [@DEU187C76]). Indeed, measurement of luteal phase urinary pregnanediol:creatinine ratio as an index of progesterone secretion has indicated that women with PCOS secret significantly lower levels of progesterone in the early luteal phase ([@DEU187C36]) despite a wide variation in the progesterone secretion index. A significantly reduced serum progesterone index was also observed in the early luteal phase of naturally ovulating oligomenorrheic women with PCOS compared with normal fertile women ([@DEU187C23]). Collectively these results support the notion that there is an inherent impairment in progesterone biosynthetic capacity of the GCs from women with PCOS.

Interestingly, this report has shown that progesterone production by GCs from women with PCOS was not acutely altered by prior exposure to metformin *in vivo*. Moreover, after 144 h of culture both progesterone synthesis and conversion of glucose to pyruvate and lactate by metformin-pretreated GCs were lower than their PCOS counterparts and Control GCs, after data were corrected for viable cell number. These results suggest that metformin exposure *in vivo* not only increased cell proliferation *in vitro* but that it also permanently slowed down the metabolism and progesterone synthetic capacity the GCs *in vitro*. It is unclear whether this negative metabolic effect was due to: reduced endothelial function in densely populated, viable GCs; substrate limitation *in vitro*; or to a direct effect of metformin on cells. These parameters may not be mutually exclusive. A significant reduction in both insulin and IGF-1-stimulated progesterone production *in vitro* has been reported in two previous studies where control and PCOS GCs were incubated with metformin in the culture medium ([@DEU187C44]; [@DEU187C75]). Additionally, human GC expression of *IGF-1* was lower after treatment with metformin prior to IVF compared with control women with PCOS ([@DEU187C61]). A sustained inhibitory effect of metformin on theca cell androgen production was also recorded during *in vitro* exposure to metformin ([@DEU187C1]). Furthermore, metformin appears to exert an insulin-independent suppressive effect on CYP17-lyase and androstenedione production by human ovarian theca-like tumour cells ([@DEU187C1]). Metformin, when added to the culture media, has also been shown to decrease the levels of the expression of steroid acute regulatory protein (StAR) in rat GCs ([@DEU187C74]). While an assessment of StAR protein levels by western blot analysis of GCs from the current experimental series would have been informative with respect to the mechanism of action of metformin, analysis of this nature was not possible in the current work due to: (i) limited number of GCs available for analysis when using an individual patient culture strategy; and (ii) the need to accurately quantify GC metabolism and steroidogenesis in relation to viable cell number, as assessed by neutral red assay, at the end of culture. Further research is required to investigate the molecular mechanisms of action of metformin on GCs.

In clinical studies, a significant reduction in serum IGF-1 and progesterone concentrations has been reported in women with PCOS treated with metformin at a dose of 850 mg three times a day for a period of 16 weeks ([@DEU187C2]). Conversely, an observational study reported a significant increase in progesterone secretion on continued use of metformin (serum level of 16.97 ng/ml) during the luteal phase as opposed to a lower serum progesterone concentration in women with PCOS not treated with metformin (4.9 ng/ml) ([@DEU187C46]). It has been suggested that metformin may exert a direct inhibitory effect on 3-hydroxy steroid dehydrogenase, StAR and aromatase enzyme activities thereby reducing steroid production by human GCs ([@DEU187C50]; [@DEU187C38]; [@DEU187C44]). Finally, AMPK activation by metformin is a mechanism favoured by [@DEU187C75] to account for reduced synthesis of steroids by rat GCs. The clinical implications of the 'metformin effect' on human GCs observed in the current study need further clinical research.

Conclusion {#s5}
==========

In conclusion, this study demonstrated that regardless of patient aetiology, insulin doses of 0.01--100 ng/ml had no effect on acute or long-term GC metabolism or on progesterone production by GCs cultured in physiological, serum-free conditions. In contrast, supplementation of media with 3--6 mM glucose consistently affected glucose consumption as well as pyruvate and lactate production by follicular GCs and long-term cultured GCs. The PCOS aetiology compromised the capacity of follicular and cultured GC to consume glucose *in vitro*, and this metabolic effect was alleviated by pretreatment with metformin *in vivo*. Prior metformin exposure *in vivo* also enhanced GC proliferation *in vitro.* GCs from patients with PCOS consistently had a significantly reduced capacity to synthesize progesterone compared with controls. These results significantly advance the existing knowledge on the perturbance of glucose metabolism by the GCs in women with PCOS by revealing reduced pyruvate production and preferential lactate production by these cells in addition to their reduced glucose uptake. This metabolic lesion may compromise the availability of GC-derived pyruvate, the key energy substrate for oocyte development and maturation, and so negatively impact on oocyte quality. The findings that metformin pretreatment *in vivo* improved acute glucose consumption and utilization by GCs and caused a reduction in long-term progesterone production by GCs are novel. Further research is required to underpin the molecular mechanisms of the effect(s) of metformin on GCs in order to optimize the clinical use of this drug.

Authors\' roles {#s6}
===============

D.M. executed the research, analysed the data and drafted the manuscript. S.E.H. assisted with GC cultures and validation of GC metabolism assays. A.H.B. supervised the clinical aspects of the research and revised the manuscript. J.H.B. conducted the insulin and glucose assays in serum and follicular fluid. B.K.C. conducted the progesterone assays at the laboratory of Nottingham University. H.M.P. designed the experimental strategy and research methodology, and supported data analysis and the drafting of the manuscript.

Funding {#s7}
=======

This work was supported by the UK Medical Research Council Grant Reference number G0800250. Funding to pay the Open Access publication charges for this article was provided by the University of Leeds, Accounts Payable, EC Stoner Building, Leeds, LS2 9JT, UK.

Accessing Research Data {#s8}
=======================

Data can be accessed via email by contacting <H.M.Picton@leeds.ac.uk>

Conflict of interest {#s9}
====================

None declared.

The authors acknowledge Mrs Ping Jin, Ms Catherine Pincott-Allen, Mr Jonathan Brent, Mrs V Sharma and Mr AJ Rutherford for their assistance with media preparation, progesterone assays, follicular fluid assays and support with patient recruitment.

[^1]: The values are mean ± SEM except for fertilization, positive pregnancy and clinical pregnancy rate. Chi^2^ and Kruskal--Wallis tests were used for statistical analysis.

[^2]: PCOS: polycystic ovary syndrome; MII: metaphase II; Metformin: women with PCOS who had been treated with metformin.

[^3]: The values are mean ± SEM for the number of analyses shown. Comparison is between the three aetiological groups for each biochemical parameter using Kruskal--Wallis test. Samples of clean catch follicular fluid were not available for all patients who consented for GC metabolism research. Therefore fewer follicular fluid samples were available for glucose and insulin measurements.
